5HVG
Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-a204)
Summary for 5HVG
Entry DOI | 10.2210/pdb5hvg/pdb |
Related | 5HVF 5HVH |
Descriptor | Carboxypeptidase B2, VHH-a204, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total) |
Functional Keywords | procarboxypeptidase u, thrombin-activatable fibrinolysis inhibitor, tafi, procarboxypeptidase r, plasma procarboxypeptidase b, nanobody, antibody fragment, protein complex, hydrolase/hydrolase inhibitor, hydrolase-hydrolase inhibitor complex |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 4 |
Total formula weight | 122698.04 |
Authors | Zhou, X.,Weeks, S.D.,Strelkov, S.V.,Declerck, P.J. (deposition date: 2016-01-28, release date: 2016-06-22, Last modification date: 2024-01-10) |
Primary citation | Zhou, X.,Weeks, S.D.,Ameloot, P.,Callewaert, N.,Strelkov, S.V.,Declerck, P.J. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. J.Thromb.Haemost., 14:1629-1638, 2016 Cited by PubMed: 27279497DOI: 10.1111/jth.13381 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.05 Å) |
Structure validation
Download full validation report